Surgery Partners, Inc.
NASDAQ:SGRYMedical - Care Facilities
+$0.06 today
- Market cap
- $3.53B
- Beta
- 1.95
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.59
Volume 3.24M
Average 1.36M
SGRY Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Surgery Partners, Inc.NASDAQ: SGRY
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures growth accelerates
Q3 FY2026 capital expenditures of $24.5M (cash outflow) rose 23.7% year over year, ahead of the -14.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.
Context
- Capital expenditures amounted to 2.4% of revenue in FY2025, down 0.5 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +23.7% holds above the trailing-twelve-month pace of -14.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (78.7M) USD
- Year-over-year change
- +12.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (78.7M) | +12.9% |
| FY2024 | 2024-12-31 | (90.4M) | -1.8% |
| FY2023 | 2023-12-31 | (88.8M) | -10.2% |
| FY2022 | 2022-12-31 | (80.6M) | -39.9% |
| FY2021 | 2021-12-31 | (57.6M) | — |
Capital Expenditures vs competitors
How SGRY compares with its peers on the latest reported figures
- SGRY's LTM Sep 2026 capital expenditures of $75.1M is the 6th largest of the 7 companies compared; the peer median is $649.79M.
- Its year-over-year change of -14.9% is the lowest of 7, against a peer median of +10.2%.
- Capital expenditures amounts to 2.2% of revenue for SGRY, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.13B | +10.4% | +4.0% | 6.6% | |
| LTM Jun 2026 | $992M | +10.0% | +9.8% | 4.5% | |
| LTM Jun 2026 | $973.58M | -2.5% | +11.4% | 5.4% | |
| LTM Mar 2026 | $326M | -7.4% | -6.9% | 1.5% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $217.08M | +16.4% | +11.9% | 3.4% |
| LTM Sep 2026 | $75.1M | -14.9% | -0.8% | 2.2% | |
| LTM Mar 2026 | $3.66M | +124.1% | -44.3% | 0.4% | |
| Peer median (excluding SGRY) | $649.79M | +10.2% | +6.9% | 4.0% | |
Competitors are the stored peer set for SGRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 70.7M | 87M | 135.3M | 12.5M | 98.9M |
| Depreciation & Amortization | 98.8M | 114.8M | 118.1M | 152.6M | 176M |
| Deferred Income Tax | 8.9M | 21.9M | (1.7M) | 131.5M | 16.7M |
| Stock-Based Compensation | 17.4M | 18.4M | 17.7M | 33.3M | 14.8M |
| Change in Working Capital | (149.1M) | (102.3M) | (62.3M) | (118.9M) | (110.4M) |
| Accounts Receivables | (32.1M) | (35.3M) | (47.2M) | (72.1M) | (53.8M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (117M) | (67M) | (15.1M) | (46.8M) | (56.6M) |
| Other Non-Cash Items | 40.4M | 19M | 86.7M | 89.1M | 78.3M |
| Operating Cash Flow | 87.1M | 158.8M | 293.8M | 300.1M | 274.3M |
| Capital Expenditures | (57.6M) | (80.6M) | (88.8M) | (90.4M) | (78.7M) |
| Acquisitions (Net) | (280.4M) | (228.7M) | (128.9M) | (378.8M) | (162.1M) |
| Purchases of Investments | 0 | 0 | 0 | (1.7M) | (13.3M) |
| Sales of Investments | 0 | 0 | 0 | 4.6M | 0 |
| Other Investing Activities | 6.3M | 1.4M | (7.9M) | (22.2M) | 7.5M |
| Investing Cash Flow | (331.7M) | (307.9M) | (225.6M) | (488.5M) | (246.6M) |
| Debt Repayment | (43.8M) | (644.2M) | 19.5M | 450.4M | 158.7M |
| Common Stock Issued | 581.8M | 882.9M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (5.1M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (216.6M) | (196.6M) | (174.7M) | (188.4M) | (216M) |
| Financing Cash Flow | 316.3M | 42.1M | (155.2M) | 262M | (57.3M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.7M | (107M) | (87M) | 73.6M | (29.6M) |
| Free Cash Flow | 29.5M | 78.2M | 205M | 209.7M | 195.6M |
Surgery Partners, Inc.
NASDAQ:SGRY
Intrinsic Alpha fair value
Locked
Current Price
$26.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.